Search bioRxiv⌕ Search

Biology subjects

Kadluczka, J.

Publications and source records attributed to Kadluczka, J..

2 recordsLinked to original sources

Minocycline treatment affects astrocyte - microglia - neuron interaction and functional compensation of motor deficits in rat model of combined fluorocitrate and 6-OHDA lesion and early Parkinson's disease

Prolonged nervous system inflammation and glia activation are among hallmarks of Parkinsons disease. There are no therapies slowing pathology. Microglia and astrocytes are considered targets for disease modifying strategies. Nigrostriatal neurodegeneration causes locomotor dysfunction but at early stages can be compensated. Interaction between neurons, microglia and astrocytes could be essential for this functional adaptation and neuronal survival in long-term. The aim was to check how microglia activation inhibition affects neuron and astrocyte cell death caused by selective toxins and how it affects locomotion and potential for spontaneous functional compensation of motor deficits at the early stages of Parkinsons disease. In a rat model of fluorocitrate (FC)-induced astrocyte death and microglia activation combined with 6-OHDA selective dopaminergic system neurodegeneration we analyzed anti-inflammatory effect of minocycline on each of the cell type and on functional behavioral output. In result, reduced microglia activation by minocycline probably prevented part of astrocytes from FC-induced cell death. Microglia inhibition caused non-dopaminergic neurodegeneration in a group treated by both neurotoxins but still enhanced compensatory potential to functionally improve walking deficits caused by dopaminergic lesion. It seems that activation of microglia by dying astrocytes vs dying neurons induced varied mechanisms. Inhibition of strong microglia activation could be protective for astrocytes but microglia is also important for neuronal adaptation, therefore suppression of its activation perturbs structural rebuilding during progressive neurodegeneration affecting functional outcome. Understanding the relationship between neuronal death, astrocyte loss of function and microglial response could help to identify new, non-neuronal pharmacological target for healing various neurodegenerative diseases. HighlightsO_LIAstrocyte death affected neuron function but neurodegeneration did not affect astrocyte survival. C_LIO_LIMicroglia was differentially activated by death of astrocytes than by neuron degeneration. C_LIO_LIMinocycline treatment decreased morphological signs of microglia activation, probably protected some astrocytes but negatively affected astrocytes in 6-OHDA lesion group. C_LIO_LIMinocycline treatment despite inducing non-dopaminergic neurodegeneration still enhanced compensatory potential to functionally improve walking after combined 6-OHDA lesion and fluorocitrate-induced astrocyte death. C_LI

neuroscience↗

Hepatic MCPIP1 protein levels are reduced in NAFLD patients and are predominantly expressed in cholangiocytes and liver endothelium

Nonalcoholic fatty liver disease (NAFLD) is characterized by the excessive accumulation of fat in hepatocytes. NAFLD can range from simple steatosis to the aggressive form called nonalcoholic steatohepatitis (NASH), which is characterized by both fatty liver and liver inflammation. Without proper treatment, NAFLD may further progress to lifethreatening complications, such as fibrosis, cirrhosis or liver failure. Monocyte chemoattractant protein-induced protein 1 (MCPIP1, alias Regnase 1) is a negative regulator of inflammation, acting through the cleavage of transcripts coding for proinflammatory cytokines and the inhibition of NF{kappa}B activity. In this study, we investigated MCPIP1 expression in the liver and peripheral blood mononuclear cells (PBMCs) collected from a cohort of 36 control and NAFLD patients hospitalized due to bariatric surgery or primary inguinal hernia laparoscopic repair. Based on liver histology data (H&E and Oil Red O staining), 12 patients were classified into the nonalcoholic fatty liver (NAFL) group, 19 into the NASH group and 5 into the control (non-NAFLD) group. Biochemical characterization of patient plasma was followed by expression analysis of genes regulating inflammation and lipid metabolism. The MCPIP1 protein level was reduced in the livers of NAFL and NASH patients in comparison to non-NAFLD control individuals. Additionally, in all groups of patients, immunohistochemical staining showed that the expression of MCPIP1 was higher in the portal fields and bile ducts in comparison to the liver parenchyma and central vein. The liver MCPIP1 protein level negatively correlated with hepatic steatosis but not with patient BMI or any other analyte. The MCPIP1 level in PBMCs did not differ between NAFLD patients and control patients. Similarly, in patients PBMCs there were no differences in the expression of genes regulating {beta}-oxidation (ACOX1, CPT1A, and ACC1) and inflammation (TNF, IL1B, IL6, IL8, IL10, and CCL2), or transcription factors controlling metabolism (FAS, LCN2, CEBPB, SREBP1, PPARA, and PPARG). We have demonstrated that MCPIP1 protein levels are reduced in NAFLD patients, but further research is needed to investigate the specific role of MCPIP1 in NAFL initiation and the transition to NASH.

molecular biology↗